United States · FDA National Drug Code directory
Atovaquone
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0121-1016_0145c97d-2d5e-4fcd-ae76-85e4ae946350
- Product NDC
- 0121-1016
- Form
- SUSPENSION
- Composition / generic term
- Atovaquone
- Labeler
- PAI Holdings, LLC dba PAI Pharma
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20240110
- Source listing expiry
- 20271231
Source-listed ingredients
- ATOVAQUONE — 750 mg/5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 3 TRAY in 1 CASE (0121-1016-18) / 6 CUP, UNIT-DOSE in 1 TRAY / 5 mL in 1 CUP, UNIT-DOSE (0121-1016-05) · 0121-1016-18
- 7 TRAY in 1 CASE (0121-1016-42) / 6 CUP, UNIT-DOSE in 1 TRAY / 5 mL in 1 CUP, UNIT-DOSE (0121-1016-05) · 0121-1016-42
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →